Exponent announces sale of BBI Group to Novo Holdings

Exponent announces that it has reached an agreement to sell BBI Group (“BBI”), a leading supplier of products and services to the global diagnostics and life sciences industries, to Novo Holdings A/S, a leading global life sciences investor, for an enterprise value of over £400 million.

Founded in 1986, BBI provides critical reagents and immunoassay development, lateral flow development, diagnostic manufacturing services, and smartphone reader technologies to a global blue-chip customer base that includes Thermo-Fisher, Merck and Siemens. The company’s market-leading brand, BBI Solutions, provides a range of products, including antibodies, antigens, labels, complementary reagents and point of care tests. BBI is headquartered in South Wales and employs over 400 employees across its sites in seven countries and four continents. Read more

Related Posts

UNE undergraduate receives BioME grant to study rare lobster larvae

A University of New England undergraduate student has received a $5,000 grant from the Bioscience Association of Maine (BioME) to fund...

23 May 2024

New initiative unites Maine’s innovators to bolster STEM research and workforce

An $8 million grant from the National Science Foundation will fund a four-year initiative led by the University of Maine to bolster STEM...

15 May 2024

Jackson Lab hires its first-ever chief scientific officer

Jackson Laboratory, based in Bar Harbor, has hired Mary Dickinson, a globally recognized geneticist, developmental biologist, and bioengineer, as executive vice...

13 May 2024